BSF Enterprise PLC is planning to raise £15 million in equity to further develop lab-grown leather, corneal repair, and cell culture media projects. The investment will help the company advance its technology platforms, strengthen commercial partnerships, and support ongoing product development in these emerging sectors. The fundraise includes convertible loan notes and warrants, with the potential to raise up to an additional £10 million if certain warrants are exercised.

A significant portion of the funding will be directed towards BSF’s subsidiary companies, Lab-Grown Leather (LGL), Kerato, and 3D Bio-Tissues (3DBT) to accelerate the commercialization of their cutting-edge technologies. BSF also plans to use part of the funds for potential acquisitions or joint ventures to further enhance its technological footprint in the bioengineered materials market. The company's CEO expressed excitement about the investment and the opportunities it presents for the company's subsidiary companies' growth and development.